EXPERT
13 Dec 2022
Trial Summary
This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.
Acronym:
EXPERT
ACTRN/NCT /ethics:
NCT02889874
Scientific title:
A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer
Sponsor / Cooperative group:
Breast Cancer Trials, Australia and New Zealand
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 50 Years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2021-08-21 |
| Anticipated End Date | 2023-12-01 |
Participating Hospitals
| Hospital | GenesisCare |
|---|---|
| Clinical Trial Coordinator | Kimberley Ruxton |
| Kimberley.Ruxton@genesiscare.com | |
| Phone | - |
| Principal Investigator | Dr Phuong Tran |
| Recruitment Status | Recruiting |